Jazz Pharmaceuticals has been highlighted as a Q2 earnings outperformer in the pharmaceuticals sector.
According to a recent report, Jazz Pharmaceuticals PLC is recognized as a top performer in Q2 earnings among pharmaceutical companies. This acknowledgment reflects the company's strong financial health and solid market position within the healthcare sector.
Advertisement
Jazz Pharmaceuticals PLC
JAZZ.US
JAZZ.US
Jazz Pharmaceuticals PLC
WealthAwesomeMarket cap
$15.32B
P/E
16.1x
52W high
$266.38
52W low
$128.80
1W change
-0.94%
Beta
0.37
Analyst Price Targets
Based on 22 analysts covering JAZZ · as of Oct 5, 2026
Wall Street analysts forecast JAZZ stock price to rise 24.7% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
C$294.27
+24.7% Upside
Current Price
C$236.04
Last close
Analyst Breakdown (22 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on JAZZ's historical volatility
30-Day Vol
26.3%
Annualized
90-Day Vol
27.6%
Annualized
Trend (90d)
-13.6%
Annualized drift
90d Mean
C$224.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$232.24 | C$212.09 – C$254.32 |
| 60 trading days | C$228.51 | C$200.97 – C$259.81 |
| 90 trading days | C$224.83 | C$192.12 – C$263.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider Jazz Pharmaceuticals' recent performance metrics and market position when evaluating their investment strategy.
Jazz Pharmaceuticals' Last Close at US$232.44
The stock's performance over the last month shows a decline of 4.36%, while year-to-date, it has increased by 36.32%.
Bull case
Jazz Pharmaceuticals boasts a profit margin of 20.4% and a return on equity (ROE) of 22.1%. These figures indicate effective management and operational efficiency.
Bear case
Despite its recent recognition, Jazz Pharmaceuticals has experienced a 4.36% decline over the past month, suggesting potential volatility in the stock's performance.
Jazz Pharmaceuticals Recognized as Q2 Earnings Outperformer
Advertisement
Jazz Pharmaceuticals has been highlighted in a report as one of the outperformers in Q2 earnings within the pharmaceuticals sector. The company closed at US$232.44, reflecting a 1-day increase of 0.16%. Over the past week, the stock has decreased by 0.94%, while it has seen a more significant decline of 4.36% over the past month. Year-to-date, however, Jazz Pharmaceuticals has shown strong performance with a gain of 36.32%.
Current Stock Performance and Valuation Metrics
The trading volume for Jazz Pharmaceuticals has been 87,906 shares, which is about 1.16 times the 20-day average volume of 731,005 shares. The stock is currently trading below its 50-day moving average of US$247.21 by 6.0% but is above its 200-day moving average of US$211.91 by 9.7%. The stock's 52-week range is between US$128.80 and US$266.38, indicating it is currently at 75% of its range. The company's P/E ratio stands at 16.145, suggesting a reasonable valuation within the sector.
Looking Ahead for Jazz Pharmaceuticals
Investors should keep an eye on upcoming earnings reports and market trends in the pharmaceuticals sector to gauge the sustainability of Jazz Pharmaceuticals' performance. Analysts have set an average target price of US$294.27 for the stock, implying a potential upside of 26.6% from its current price. Given the company's solid fundamentals, including a profit margin of 20.4% and a return on equity of 22.1%, there are indications of strong operational efficiency that may benefit future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
